Cargando…

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence

About ten years ago, the first results of the so-called “Bangladesh regimen”, a short regimen lasting nine months instead of 20 months, revolutionized multidrug-resistant tuberculosis (MDR-TB) treatment. Similar short regimens were studied in different settings, relying for their efficacy on a later...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trébucq, Arnaud, Decroo, Tom, Van Deun, Armand, Piubello, Alberto, Chiang, Chen-Yuan, Koura, Kobto G., Schwoebel, Valérie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019808/ https://www.ncbi.nlm.nih.gov/pubmed/31881691 http://dx.doi.org/10.3390/jcm9010055

Ejemplares similares

Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries
por: Schwœbel, Valérie, et al.
Publicado: (2020)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen
por: Lempens, Pauline, et al.
Publicado: (2020)

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2020)

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Van Deun, Armand, et al.
Publicado: (2021)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials
por: Moodley, Riya, et al.
Publicado: (2016)

Trends in tuberculosis clinicians’ adoption of short-course regimens for latent tuberculosis infection
por: Feng, Pei-Jean I., et al.
Publicado: (2023)

Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases
por: Ngabonziza, Jean Claude S, et al.
Publicado: (2021)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States
por: Sinha, Pranay, et al.
Publicado: (2023)

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
por: Nunn, Andrew J, et al.
Publicado: (2014)

Efficacy of directly observed treatment short-course intermittent regimen in spinal tuberculosis
por: Valsalan, Rejith, et al.
Publicado: (2012)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Trauer, James M., et al.
Publicado: (2016)

Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh
por: Lempens, Pauline, et al.
Publicado: (2023)

Implementation of the ‘Removed Injectable modified Short-course regimens for EXpert Multidrug Resistant Tuberculosis’ (RISE study) in Tanzania: a protocol for a mixed-methods process evaluation
por: Kalolo, Albino, et al.
Publicado: (2022)

Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis
por: Jain, Kalpesh, et al.
Publicado: (2014)

Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies
por: Mahardani, Putu Nandika, et al.
Publicado: (2022)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain
por: Eldholm, Vegard, et al.
Publicado: (2015)

A DECADE TREND OF MULTIDRUG RESISTANT TUBERCULOSIS IN SÃO PAULO STATE, BRAZIL
por: BOLLELA, Valdes Roberto, et al.
Publicado: (2016)

Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality
por: Mitnick, Carole D., et al.
Publicado: (2013)

Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment
por: Tierney, Dylan B., et al.
Publicado: (2014)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022)

Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2017)

Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen
por: Achar, Jay, et al.
Publicado: (2015)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial
por: Zheng, Xubin, et al.
Publicado: (2023)

Maternal Anaemia at Delivery and Haemoglobin Evolution in Children during Their First 18 Months of Life Using Latent Class Analysis
por: Koura, Kobto G., et al.
Publicado: (2012)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9nt4as6bff0o31k1bntt783rtp